Daniel P. Petrylak, MD, comments on advances in the management of high-risk locally advanced prostate cancer, touching on some of the related proce......READ MORE
Daniel P. Petrylak, MD, comments on new and emerging data on the assessment and treatment of patients with metastatic hormone-sensitive prostate ca......READ MORE
Peter R. Carroll, MD, MPH, discusses the differences between gonadotropin-releasing hormone (GnRH) agonists and antagonists and the appropriate use......READ MORE
Peter R. Carroll, MD, MPH, reflects on AUA2021 proceedings, commenting on current capabilities and best practices for performing prostate biopsies.......READ MORE
The optimal use of ablative therapies for prostate cancer is an evolving area that promises to influence the future of urologic oncology. Speakers ......READ MORE
During a plenary session at AUA2021, William T. Lowrance, MD, MPH, MBA, from the Huntsman Cancer Institute at the University of Utah, delivered a p......READ MORE
